Evommune, Inc. (EVMN)
Healthcare
Biotechnology
11.50 $
Closing price · As of: 20. Jul 2026
🔔 Watch stock
Appears in These Scanners
This stock currently matches 9 of our scanner strategies — each hit links to the scanner.
Quality & Balance Sheet
Breakout & Setup
Momentum & Trend
Risk & Weakness
Only genuine hits from verified scanners count; pure ranking metrics (P/E, P/S, and similar, which just sort the whole universe) don't count as a hit. Scanners marked in red are red-flag signals (risk/short scanners) — appearing there is not a seal of approval. View all scanners
Basics
Market Cap
The value of the entire company on the market: share price times total shares outstanding.
0.9Mrd. $
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
36Mio.
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
55.5%
Beta
Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market.
–
Performance
Perf. 1M
Price performance over the last month.
-35.50%
Perf. 3M
Price performance over the last 3 months.
-32.10%
Perf. 6M
Price performance over the last 6 months.
-14.40%
YTD Performance (%)
Price performance since the start of the year (Year to Date).
41.60%
52-Week-High Distance
How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high.
-27.3%
Valuation
P/E
Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E.
–
Forward P/E
P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future.
0.0
PEG
P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey.
–
P/B
Price-to-book ratio: market value relative to book equity.
2.9
P/S
Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable.
–
EV/EBITDA
Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero.
0.0
Price/FCF
Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up.
–
Profitability
Gross Margin
Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power.
100.0%
EBIT Margin
EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes.
–
Net Margin
Net margin: what's left of sales as profit after ALL costs, interest, and taxes.
0.0%
Return on Equity
Return on equity: how much profit does the company generate per year on shareholders' equity?
-45.0%
Return on Assets
Return on assets: how much profit the company generates from its total assets (equity and debt combined).
-29.7%
Balance Sheet & Safety
Equity Ratio
Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet.
–
Debt/Equity
Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity.
0.03
fortress balance sheet
Altman Z
Edward Altman's bankruptcy early-warning score: under 1.8 = danger zone, over 3 = safe. Values well above that mean a very resilient balance sheet.
21.25
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
4 von 9
Growth
Sales Growth Last Quarter
Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY).
0.00%
EPS Growth Last Quarter
Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY).
0.00%
Sales Growth (Year)
Sales growth in the last fiscal year versus the year before.
85.71%
Forward Sales Growth
Sales growth analysts expect over the next 12 months — an estimate, not a guarantee.
-73.30%
Forward EPS Growth
Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee.
-16.50%
Quality & Screener
Stage
Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line.
2
RS Rating
Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks.
54
EPS Rating
Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth.
42
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
4 von 9
Fundamental Rating
Our own Fundamental Rating from −100 to +100 with an A+ to F grade: growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety, all percentile-ranked.
D (-36 von 100)
fortress balance sheet
Altman Z
Edward Altman's bankruptcy early-warning score: under 1.8 = danger zone, over 3 = safe. Values well above that mean a very resilient balance sheet.
21.25
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.51 | – | 0 | – | – | -22 | -22 |
| 2025: Q1 | -0.40 | – | 3 | – | -485.20 | -24 | -24 |
| 2025: Q2 | -0.38 | – | – | – | – | -26 | -26 |
| 2025: Q3 | -0.35 | – | 10 | – | -124.80 | -10 | -10 |
| 2025: Q4 | -0.78 | – | 0 | – | – | -17 | -17 |
| 2026: Q1 | -0.60 | – | 0 | -100.00 | – | -28 | -28 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
Evommune, Inc. ist ein Biotechnologieunternehmen in der klinischen Phase in den USA.
| Employees | 48 |
|---|---|
| Headquarters | Palo Alto, CA |
| Website | evommune.com |
| IPO Date | 6. Nov 2025 |
| Next Earnings | 6. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Luis C. Pena | Founder, President, CEO & Director | 1963 |
| Kyle Carver CPA, M.B.A. | Chief Financial Officer | 1988 |
| Gregory S. Moss Esq. | Chief Business & Legal Officer, Corporate Secretary and Chief Compliance Officer | 1984 |
| Eugene Andrew Bauer M.D. | Co-Founder, Chief Medical Officer & Director | 1942 |
| Jeegar Patel Ph.D. | Chief Scientific Officer | 1978 |
| Janice Drew M.P.H. | Chief of Development Operations | 1963 |
| Lou Sehl Ph.D. | Senior Vice President of Technical Operations | – |
| Daniel J. Burge M.d. | Senior Vice President of Clinical Development | 1962 |
| J. Mark Jackson M.D. | Senior Vice President of Clinical Development | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 20, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.